Home » Authors » Jim Shrine

Articles by Jim Shrine

Labopharm Falls 50 Percent On Second FDA Approvable Letter

June 4, 2007

Cypress Raises $72.9M Publicly Following Phase III Trial Success

June 1, 2007

Cypress Raises $72.9M Publicly Following Phase III Trial Success

June 1, 2007

Gilead Reports Positive Phase III Results On CF Drug; Plans NDA

May 31, 2007

Gilead Reports Positive Phase III Results On CF Drug; Plans NDA

May 31, 2007

Allon Completes C$15M Funding For Neurodegenerative Programs

May 30, 2007

Allon Completes C$15M Funding For Neurodegenerative Programs

May 30, 2007

Avalon Raises $20M Privately To Fund Drug Development

May 29, 2007

Avalon Raises $20M Privately To Fund Drug Development

May 29, 2007

Celldex Starts Phase II/III Trial Of Peptide Vaccine In Brain Cancer

May 25, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 11, 2024.
Boryung invests $10M in Intuitive Machines for outer space R&D
BioWorld
Following its $60 million investment in Axiom Space Inc. last year, Boryung Co. Ltd. made a $10 million private placement in Intuitive Machines Inc. to grow its...
Phase II Huntington’s tie-up with Novartis could edge $3B for PTC
BioWorld
PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the firm’s Huntington’s disease program with...
Elevar nabs Relay’s FGFR2 rare cancer drug in $500M deal
BioWorld
Elevar Therapeutics Inc. will license Relay Therapeutics Inc.’s “NDA-ready” bile duct cancer therapy, lirafugratinib (RLY-4008), through a potential $500 million...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.